BioMap Unveils 11 AI Life-Science Collaborations at Hong Kong Summit

BioMap announced collaborations with 11 partners at the International Bio-Computing Innovation Summit 2026 in Hong Kong on November 6, extending its AI foundation-model work across drug research, traditional Chinese medicine, agricultural breeding and overseas market expansion. Seven projects were presented at the morning launch ceremony for BioMap InnoHub, and four additional organizations joined at an afternoon ceremony held at the Hong Kong Convention and Exhibition Centre.

BioMap hosted the summit with support from Hong Kong Investment Corporation Limited (HKIC), the state-backed investment vehicle. The stated purpose is twofold: advance AI research and applications in life sciences, and accelerate the commercialization of research outcomes in Hong Kong. The stakes are concrete for a city positioning itself as a biotech hub, because foundation models — large neural networks trained on broad biological data that can be adapted to many downstream tasks — only matter commercially if partners convert model outputs into validated products.

What did the medical projects cover?

The University of Hong Kong collaboration advances the next phase of the Breast Cancer Virtual Cell Large Model project, which uses AI to simulate breast-cancer cell functioning and help researchers understand the disease. HKIC CEO Clara Chan said in her November 6 summit speech that the breast-cancer model's phase II was launching in 2026, after an earlier multimodal breast-cancer tumor-cell foundation model was released at the 2025 summit.

Two other morning projects apply AI to different forms of therapeutic research:

• BioMap and Hong Kong Baptist University plan to establish an AI Traditional Chinese Medicine Joint Laboratory, combining computational analysis with experimental validation to investigate how traditional Chinese medicine ingredients work.
• A Novel Peptide Drug Incubation initiative with PepLib is intended to accelerate research and development of peptide and cyclic peptide therapeutics, two structural classes that have become prominent in modern drug discovery.

The HKU project carries the most direct clinical framing of the group. Its phase II launch in 2026 gives the partnership a dated milestone against which progress can be measured, a year after the 2025 foundation-model release established the technical baseline.

How does AI enter agriculture?

Agriculture received a parallel push. BioMap and Soy-Sky FarmTech will combine biological foundation models with crop genetic and trait data in an AI Breeding Platform designed to support breeding decisions. The partners also plan a Belt and Road AI Agricultural Innovation Ecosystem, a framework that ties the breeding work to China's broader infrastructure and trade initiative.

Separately, BioMap will work with DEFTA Partners on the DEFTA Overseas Market Expansion Program, exploring research and industry collaboration in Japan and other overseas markets. That program extends the announcement's geographic reach beyond Hong Kong and mainland China into markets where BioMap has less established presence.

Which projects build shared infrastructure?

Several collaborations concentrate on infrastructure connecting models with experiments. BioMap's initiative with Coyote Bioscience combines research translation across industry, academia and research institutions with an open cartridge ecosystem, and supports collaboration on molecular point-of-care testing in Hong Kong. Its work with HiDream.ai on a Cross-Scale Virtual Organism Model will study biological phenomena at different scales and explore ways to predict and reconstruct their dynamics — an approach aimed at modeling living systems rather than isolated molecular targets.

The afternoon ceremony added two planned facilities:

• Temasek Life Sciences Laboratory: BioMap said it would work with the Singapore-based institution on plans to jointly establish an AI Bio-Computing Center in Singapore. The center remains at the planning stage.
• Revvity: the partner for another planned facility, an AI biomanufacturing laboratory integrating computational and experimental workflows in a closed loop, meaning model predictions directly drive automated experiments whose results feed back into the models.

Both facilities are plans rather than operating labs. The Singapore center's planning-stage status marks it as the earliest-phase item among the 11 collaborations.

What is MegaStream TechBio?

The afternoon program also featured MegaStream TechBio, the drug-development venture jointly established by BioMap and Harbour BioMed. CEO Kyler Lei made his first public appearance, outlined a drug-discovery vision called AIDD 3.0 and discussed a pipeline organized around First-in-Class and Best-in-Class programs — drug candidates that are either mechanistically novel or superior to existing therapies in their class.

That presentation built on a partnership already disclosed earlier in the year. Harbour BioMed's June 15, 2026 announcement said the companies would launch MegaStream as an AI-native pipeline company targeting global markets.

Under that plan, the division of labor is explicit. Harbour BioMed would contribute its fully human antibody platform, target-biology expertise and global clinical-development capabilities. BioMap would supply foundational AI technology, model engineering and intelligent research-and-development capabilities. MegaStream's initial pipeline was to combine candidates identified by AI in the partners' earlier collaborations with newly launched AI-driven discovery programs, prioritizing complex biologics across cardiovascular, renal, oncology and anti-aging areas.

What targets did Harbour BioMed set in June?

The June release also described a planned dry-wet discovery laboratory, a facility linking computational design ("dry") with experimental validation ("wet"). Harbour Biomed projected three operating figures for that laboratory:

• Efficiency gains above 500% over previous-generation platforms
• A more than tenfold increase in data-accumulation efficiency
• Over 5 petabytes of AI-ready life-science data within five years

Those figures are operating targets for the planned laboratory, not performance results announced at the November summit. The distinction matters for anyone tracking AI drug-discovery claims, because projected efficiency multiples in this sector frequently precede, rather than follow, demonstrated results.

Why do the 11 partnerships matter together?

The breadth is the story. The 11 collaborations span oncology modeling, traditional Chinese medicine mechanistic research, peptide therapeutics, crop breeding, point-of-care diagnostics, whole-organism modeling, biomanufacturing and two international outposts in Singapore and Japan. No single project carries the announcement; the network does.

The commercialization framing is equally deliberate. HKIC's involvement, through CEO Clara Chan's summit speech and the corporation's support role, ties the research agenda to Hong Kong's economic strategy of converting scientific output into companies and jobs. The BioMap InnoHub launch ceremony, which anchored the morning's seven presentations, functions as the organizational vehicle for that conversion.

For BioMap, the execution test is whether this expanding network can turn model predictions and automated experiments into validated therapies, breeding tools and commercial research outcomes across the regions covered by the summit partnerships. The November 6 announcement sets the commitments; the 2026 phase II breast-cancer model launch and the planned Singapore center are the nearest dated checkpoints for judging delivery.